New chemotherapy approach for treating stomach cancer
Editor's note: November is Stomach Cancer Awareness Month.
By DeeDee Stiepan
Stomach cancer is caused by an uncontrolled growth of cells that starts in the stomach. Most stomach cancers are found when the disease has spread beyond the stomach, when a cure is less likely.
Mayo Clinic experts are exploring new ways to help patients with late-stage cancers. A new approach to treating stomach cancers called hyperthermic intraperitoneal chemotherapy (HIPEC) delivers heated liquid chemotherapy directly to the abdomen where it can target the cancer. In this Mayo Clinic Minute, Travis Grotz, M.D., a Mayo Clinic surgical oncologist, discusses how HIPEC works and the potential benefits of the treatment.
During a HIPEC treatment, the abdominal cavity is bathed with hot chemotherapy to kill any microscopic cancer cells.
"The chemo can stay locally in that region, the abdomen, and then it can continue to work even past the procedure. And then that allows us to use really high concentrations of the chemo directly where the cancer is," says Dr. Grotz.
HIPEC has been used as a treatment for other cancers for several decades, but just recently has been adapted to stomach cancer.
"We use the kind of a different combination of drugs that we've come up with based on other research and data and experience, and put them together and found that, in our experience, that they were more synergistic. They work together to kill the cancer cells very well. Our outcomes were quite a bit better than kind of traditional systemic chemotherapy," says Dr. Grotz.
The outcomes have been significantly better than those achieved with traditional chemotherapy. However, Dr. Grotz notes that more studies are ongoing.
"We want to improve survival, help people live longer, spend more time with their family, do it in a way that's safer, and has less complications and risks to patients," says Dr. Grotz.
Learn more
Learn more about stomach cancer and find a clinical trial at Mayo Clinic.
Join the Cancer Support Group on Mayo Clinic Connect, an online community moderated by Mayo Clinic for patients and caregivers.
Also, read these articles:
- New heated drug baths provide hope for patients with stomach cancer
- Dear Mayo Clinic: Signs of stomach cancer? Diagnosis and treatment
- Gene biomarker may predict gastric cancer survival, treatment response
A version of this article was originally published on the Mayo Clinic News Network.
Related Posts
Mayo Clinic study shows a new approach to chemotherapy more than doubles the typical survival rate for people with stomach cancer.
Dr. Travis Grotz, a Mayo Clinic surgical oncologist, explains the symptoms, diagnosis and treatment of stomach cancer.
Researchers have identified a gene biomarker associated with overall survival and treatment response in people with gastric cancer.